Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 01, 2022

Reduced-Dose Post-Transplant Cyclophosphamide and Anti-Thymocyte Globulin Regimen as Graft-vs-Host Disease Prophylaxis in Patients With Hematological Malignancies Who Underwent Haplo-HSCT

British Journal of Haematology

 

Additional Info

British Journal of Haematology
Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial
Br. J. Haematol 2022 Oct 06;[EPub Ahead of Print], W Zhang, R Gui, Y Zu, B Zhang, Z Li, Y Zhang, X Wang, S Guo, X Zhan, Y Fu, Y Song, J Zhou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading